Cervical Carcinoma Clinical Trial
Official title:
Cervical Cytology - Do SMS Reminders Increase Participation in the Cervical Screening Programme?
This study will pilot production and evaluate the use of reminder information in women invited for cervical screening for the first time within the GGC eligible population for cervical screening. Women aged under 30 years will be identified to receive an SMS text message following their cervical screening invitation using information from the CHI Broadcast.
Cervical cancer is the commonest cancer among women aged less than 35 years. A change to the
age range and frequency for cervical screening was implemented on the 6th June 2016. This
increased the younger eligible age for screening from 20 to 25. Uptake of cervical screening
among women in the youngest eligible age range has historically been low. Research by Scott
Porter has shown that cervical screening is not on young women's radar and additionally there
is scope for confusion amongst women in this cohort about the requirement to attend for
cervical screening if they have been previously immunised against HPV (human papilloma virus)
generally in secondary school in year 2, some 12 years earlier.
The HPV vaccine was introduced in 2008 and is designed to protect against the two types of
high risk HPV which cause approximately 75% of all cervical cancer. Advice to all eligible
women who have been vaccinated remains that participation in cervical screening is necessary
to provide the most comprehensive protection against cervical cancer, as the current vaccine
does not provide protection against all high risk cancer causing strains of HPV.
Research from other screening programmes has also shown that where individuals engage with a
screening programme from the start, they are more likely to continue to participate in
screening for as long as they are eligible.
"Intending to, but not getting round to it", is the reason most associated with non-response
to cervical cancer screening invitations.
GGC serves approximately 40% of the total Scottish population and therefore testing the
reminder in the GGC population provides an opportunity to compare the impact of the SMS text
reminder in this cohort with management as usual within the remainder of the Scottish
eligible population. This should enable us to identify whether use of a reminder SMS text
message is in fact likely to add value and increase participation in cervical screening.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05458869 -
Evaluating the Human Papillomavirus Self-Collection Experience in Individuals Who Have Experienced Sexual Trauma
|
||
| Not yet recruiting |
NCT04483557 -
Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve Fertility
|
Phase 2 | |
| Terminated |
NCT04099277 -
A Study of LY3435151 in Participants With Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04452526 -
I Vaccinate: Testing Multi-Level Interventions to Improve HPV Vaccination
|
N/A | |
| Active, not recruiting |
NCT04443296 -
Study of Tumor Infiltrating Lymphocytes Following CCRT in the Treatment of Patients With Cervical Carcinoma
|
Phase 1 | |
| Recruiting |
NCT05180851 -
Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical Study
|
Early Phase 1 | |
| Withdrawn |
NCT03220009 -
Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
|
Phase 2 | |
| Completed |
NCT02460237 -
HPV Self-Test Intervention in Ohio Appalachia
|
N/A | |
| Terminated |
NCT00924066 -
Ixabepilone to Treat Cervical Cancer
|
Phase 2 | |
| Completed |
NCT04208724 -
Support Program for Adoption of Cancer Screening Interventions at a Rural Community-Based Organization
|
N/A | |
| Completed |
NCT03307044 -
Fractional CO2 Laser Therapy for Survivors of Breast Malignancies
|
N/A | |
| Recruiting |
NCT05139368 -
Hypofractionated Radiotherapy for the Treatment of Cervical or Endometrial Cancer
|
N/A | |
| Completed |
NCT03180294 -
Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer
|
Phase 2 | |
| Recruiting |
NCT05366478 -
A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT03849469 -
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
|
Phase 1 | |
| Terminated |
NCT03345784 -
Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers
|
Phase 1 | |
| Completed |
NCT02523365 -
HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Cervical Carcinoma
|
Phase 1/Phase 2 | |
| Completed |
NCT03372720 -
Fractional CO2 Laser Therapy in Minimizing Genitourinary Syndrome of Menopause in Gynecological Cancer Survivors
|
N/A | |
| Active, not recruiting |
NCT03752398 -
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
|
Phase 1 | |
| Active, not recruiting |
NCT00867464 -
Extended Follow Up of Young Women in Costa Rica Who Received Vaccine for Human Papillomavirus Types 16 and 18 and Unvaccinated Controls
|